The investigation and management of inherited thrombophilia

被引:29
作者
Cumming, AM [1 ]
Shiach, CR [1 ]
机构
[1] Manchester Royal Infirm, Univ Dept Haematol, Manchester M13 9WL, Lancs, England
来源
CLINICAL AND LABORATORY HAEMATOLOGY | 1999年 / 21卷 / 02期
关键词
thrombophilia; venous thromboembolism; laboratory diagnosis; inherited disorders; clinical management;
D O I
10.1046/j.1365-2257.1999.00210.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inherited thrombophilia can be defined as a genetically determined tendency to venous thromboembolism. Genetic risk factors for venous thrombosis include antithrombin deficiency, protein C deficiency, protein S deficiency, activated protein C resistance due to the factor V gene Leiden mutation, inherited hyperhomocysteinaemia, elevated factor VIII levels and the prothrombin gene G20210A variant. A genetic risk factor is now identifiable in up to 50% of unselected patients with venous thrombosis, Individuals with inherited thrombophilia may develop venous thrombosis at a young age, or they may present with thrombosis at an unusual site or in the apparent absence of any precipitating event. A family history of thrombosis is suggestive of inherited thrombophilia. Laboratory investigations for inherited thrombophilia should include testing for activated protein C resistance and the factor V gene Leiden mutation, and screening for deficiencies of antithrombin, protein C or protein S. Screening for the prothrombin gene G20210A variant, and measurement of plasma factor VIII and homocysteine levels should be considered in individual cases. In recent years the multifactorial nature of thrombophilia, both circumstantially and on a genetic level, has become increasingly apparent. Individuals with more than one inherited thrombophilia risk factor are particularly prone to thrombosis and their identification is a priority.
引用
收藏
页码:77 / 92
页数:16
相关论文
共 136 条
[11]  
BERTINA RM, 1995, THROMB HAEMOSTASIS, V74, P449
[12]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
[13]  
Borgel D, 1997, THROMB HAEMOSTASIS, V78, P351
[14]  
Brandt G, 1998, THROMB HAEMOSTASIS, V79, P567
[15]  
Brenner B, 1996, BLOOD, V88, P877
[16]   Activated protein C resistance can be associated with recurrent fetal loss [J].
Brenner, B ;
Mandel, H ;
Lanir, N ;
Younis, J ;
Rothbart, H ;
Ohel, G ;
Blumenfeld, Z .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) :551-554
[17]   Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene [J].
Brown, K ;
Luddington, R ;
Williamson, D ;
Baker, P ;
Baglin, T .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (04) :907-909
[18]   THE NATURAL-HISTORY AND EPIDEMIOLOGY OF VENOUS THROMBOSIS [J].
CARTER, CJ .
PROGRESS IN CARDIOVASCULAR DISEASES, 1994, 36 (06) :423-438
[19]   HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE [J].
CLARKE, R ;
DALY, L ;
ROBINSON, K ;
NAUGHTEN, E ;
CAHALANE, S ;
FOWLER, B ;
GRAHAM, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1149-1155
[20]   RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PARTIAL DEFICIENCY OF PROTEIN-S [J].
COMP, PC ;
ESMON, CT .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (24) :1525-1528